{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T21:58:54Z","timestamp":1776722334884,"version":"3.51.2"},"reference-count":22,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["5\/3\/8\/48\/ITR\u2010F\/2019\u2010ITR"],"award-info":[{"award-number":["5\/3\/8\/48\/ITR\u2010F\/2019\u2010ITR"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>The poly(lactic\u2010co\u2010glycolic) acid (PLGA) nanoparticles of tubercular drugs have been demonstrated to have a sustained release profile over 7\u2009days. There is no information on the location or mode of release of these nanoparticles in living systems. Therefore, we have planned the study to explore the pharmacokinetics and biodistribution of PLGA rifampicin nanoparticles in healthy human volunteers. We aim to study the distribution pattern of PLGA\u2010loaded nano\u2010formulation of radiolabelled rifampicin in humans.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Rifampicin was labelled with <jats:sup>99m<\/jats:sup>Tc by indirect method and nanoparticles were prepared by a single emulsion evaporation method. To investigate the pharmacokinetics and biodistribution of nanoparticles, a single dose of 450\u2009mg of rifampicin was administered orally to healthy human volunteers divided into two different groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Following a single oral dosage of the rifampicin nanoformulation, the pharmacokinetic (PK) parameters were significantly different between the nanoparticle and conventional groups: area under the concentration\u2013time curve (AUC\u2009=\u2009113.8 <jats:italic>vs<\/jats:italic>. 58.6; <jats:italic>P<\/jats:italic>\u2009&lt;\u2009.001), mean residence time (MRT\u2009=\u200916.2 <jats:italic>vs<\/jats:italic>. 5.8; <jats:italic>P<\/jats:italic>\u2009&lt;\u2009.01) and elimination rate constant (K<jats:sub>e<\/jats:sub>\u2009=\u20090.04 <jats:italic>vs<\/jats:italic>. 0.10; <jats:italic>P<\/jats:italic>\u2009&lt;\u2009.05). Also, Single\u2010photon emission computed tomography\/computed tomography (SPECT\/CT) images revealed biodistribution of nanoparticles in the distal portions of the intestine, which is consistent with our dosimetry analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Significant difference in PK parameters and biodistribution of nanoparticles in spleen and lymph nodes with maximum deposition were observed in the large intestine. The nanoparticle distribution pattern may be advantageous for the treatment of intestinal or lymph node tuberculosis (TB) and has the potential to result in a lower dose of rifampicin nanoformulation for the treatment of pulmonary TB.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.15875","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T03:58:46Z","timestamp":1691553526000},"page":"3702-3714","source":"Crossref","is-referenced-by-count":11,"title":["Bio\u2010evaluation of poly(lactic\u2010co\u2010glycolic) acid nanoparticles loaded with radiolabelled rifampicin"],"prefix":"10.1111","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8017-7815","authenticated-orcid":false,"given":"Imran","family":"Rather","sequence":"first","affiliation":[{"name":"Department of Pharmacology PGIMER  Chandigarh India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7053-003X","authenticated-orcid":false,"given":"Nusrat","family":"Shafiq","sequence":"additional","affiliation":[{"name":"Department of Pharmacology PGIMER  Chandigarh India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaya","family":"Shukla","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine PGIMER  Chandigarh India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gurvinder","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine PGIMER  Chandigarh India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Somit","family":"Pandey","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine PGIMER  Chandigarh India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritika Kondel","family":"Bhandari","sequence":"additional","affiliation":[{"name":"Department of Pharmacology PGIMER  Chandigarh India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avaneesh Kumar","family":"Pandey","sequence":"additional","affiliation":[{"name":"Department of Pharmacology PGIMER  Chandigarh India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. R.","family":"Mittal","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine PGIMER  Chandigarh India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. K.","family":"Khuller","sequence":"additional","affiliation":[{"name":"Department of Biochemistry PGIMER  Chandigarh India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Navneet","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of General Medicine PGIMER  Chandigarh India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir","family":"Malhotra","sequence":"additional","affiliation":[{"name":"Department of Pharmacology PGIMER  Chandigarh India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,9,4]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"Global tuberculosis report2020.https:\/\/www.who.int\/publications\/i\/item\/9789240013131. Accessed January 17 2022."},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13018\u2010014\u20100124\u20101"},{"issue":"8","key":"e_1_2_10_4_1","first-page":"68","article-title":"Importance of therapeutic drug monitoring of rifampin","volume":"64","author":"Chawla PK","year":"2016","journal-title":"J Assoc Physicians India"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1166\/JBN.2011.1244"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1590\/S1413\u201086702006000600003"},{"issue":"6","key":"e_1_2_10_7_1","first-page":"459","article-title":"Oral poly(lactide\u2010co\u2010glycolide) nanoparticle based antituberculosis drug delivery: toxicological and chemotherapeutic implications","volume":"44","author":"Pandey R","year":"2006","journal-title":"Indian J Exp Biol"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.INTIMP.2015.09.011"},{"key":"e_1_2_10_9_1","volume-title":"DY\u2010675\u2010G7\u2010poly(lactic\u2010co\u2010glycolic acid) nanoparticles","author":"Leung K","year":"2004"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.TIPS.2006.04.004"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh411"},{"issue":"4","key":"e_1_2_10_12_1","article-title":"Biodistribution and pharmacokinetics of recombinant \u03b11\u2010microglobulin and its potential use in radioprotection of kidneys","volume":"5","author":"Ahlstedt J","year":"2015","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/978\u20101\u20104419\u20100720\u20102_43"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/JAC\/DKG477"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/IJERPH17155626"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002429"},{"issue":"8","key":"e_1_2_10_17_1","first-page":"722","article-title":"Pharmacokinetics of rifampicin in experimental animals","volume":"21","author":"Koroleva VG","year":"1976","journal-title":"Antibiotiki"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/J.1440\u20101746.2004.03492.X"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20031253"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0169\u2010409X(90)90020\u2010S"},{"key":"e_1_2_10_21_1","volume-title":"Physiology, zero and first order kinetics","author":"Borowy CS","year":"2022"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/PHARMACEUTICS11120658"},{"key":"e_1_2_10_23_1","unstructured":"Rifampicin.https:\/\/inchem.org\/documents\/pims\/pharm\/rifam.htm#SectionTitle:6.5%20Elimination%20by%20route%20of%20exposure. Accessed June 23 2023."}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15875","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T08:03:29Z","timestamp":1702109009000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,4]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1111\/bcp.15875"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15875","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,4]]}}}